Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EVALUATION OF THE EFFICACY AND SAFETY OF DILTIAZEM 300 MG RETARD IN HYPERTENSIVE PATIENTS WITH CHRONIC-RENAL-FAILURE
Autore:
BERNADETMONROZIES P; POILLEUX E; SUC JM;
Indirizzi:
LAB SYNTHELABO,23-25 AVE MORANE SAULNIER F-92360 MEUDON FRANCE CHU RANGUEIL,SERV NEPHROL & HEMODIALYSE F-31054 TOULOUSE FRANCE
Titolo Testata:
Annales de cardiologie et d'angeiologie
fascicolo: 8, volume: 47, anno: 1998,
pagine: 589 - 594
SICI:
0003-3928(1998)47:8<589:EOTEAS>2.0.ZU;2-H
Fonte:
ISI
Lingua:
FRE
Keywords:
SUSTAINED RELEASE DILTIAZEM; MILD-TO-MODERATE HYPERTENSION; STABLE CHRONIC RENAL FAILURE; ANTIHYPERTENSIVE EFFICACY; SAFETY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
6
Recensione:
Indirizzi per estratti:
Citazione:
P. Bernadetmonrozies et al., "EVALUATION OF THE EFFICACY AND SAFETY OF DILTIAZEM 300 MG RETARD IN HYPERTENSIVE PATIENTS WITH CHRONIC-RENAL-FAILURE", Annales de cardiologie et d'angeiologie, 47(8), 1998, pp. 589-594

Abstract

31 male and female patients, between the ages of 18 and 65 years, presenting mild-to-moderate hypertension (DBP between 95 and 114 mmHg) and stable chronic renal failure (creatinine clearance between 60 and 25ml/min) after a preinclusion placebo phase were included in a multicentre open study designed to evaluate the clinical, electrocardiographic and laboratory safely, as well as the antihypertensive efficacy of Diltiazem 300 mg Retard, as monotherapy for 3 months, or combined with a diuretic (furosemide) or angiotensin converting enzyme inhibitor (captopril) for 45 days. After an 8-day placebo run-in period, the study consisted of a 45-day phase of strict monotherapy with Diltiazem 300 mg Retard, followed by a final 45-day phase during which either monotherapy was continued (if safety was satisfactory and supine DBP less than or equal to 90 mmHg), or two-agent combination therapy was instituted (when supine DBP was between 91 and 115 mmHg), 6 clinical evaluations were performed during the 3 months of this trial. Overall, 21 patients (mean age: 50+/-14 years) completed the study until the 3rd month: 13 remained on monotherapy, and 8 required two-agent combination therapy. Supine and standing systolic and diastolic blood pressures and heart rate were significantly decreased. The number of responding patients controlled (supine DBP less than or equal to 90 mmHg) progressed between D10 (40%) and D90 (57%). The observed adverse events and reasons for drop-outs from the trial for adverse events were mostly related tothe vasodilator effects of Diltiazem. The cardiac safety was good, with no significant variation of the PR interval on the ECG (0.15+/-0.03sec on D-8, 0.17+/-0.02 sec on D90). No marked modification of blood and urinary laboratory constants (serum electrolytes, blood glucose, liver function tests) was observed during this trial. Renal function, evaluated by creatinine clearance, was not altered by treatment (40.5+/-15.2 ml/min on D0, 41.7+/-16.9 ml/min on D90). Overall, this study confirmed the good clinical, laboratory and electrocardiographic safety as well as the antihypertensive efficacy of Diltiazem 300 mg Retard administered as monotherapy for 3 months or possibly in combination for 45 days, in hypertensive patients with chronic renal failure.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 00:27:33